Skip to main content
Clinical Trials/NCT00263952
NCT00263952CompletedPhase 3

Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.

Allergopharma GmbH & Co. KG2 sites in 1 countryStarted: March 1, 2003Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Locations
2

Study Overview

Brief Summary

The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • History of bee venom allergy,
  • Positive RAST for bee venom,
  • Positive skin prick test for bee venom

Exclusion Criteria

  • Serious chronic diseases

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials